Laura Gieldon

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6559153/publications.pdf

Version: 2024-02-01

18	563	759233 12	839539 18
papers	citations	h-index	g-index

20	20	20	1300
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Assigning evidence to actionability: An introduction to variant interpretation in precision cancer medicine. Genes Chromosomes and Cancer, 2022, 61, 303-313.	2.8	15
2	Germ cell mosaicism for AUTS2 exon 6 deletion. American Journal of Medical Genetics, Part A, 2021, 185, 1261-1265.	1.2	2
3	Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers. Cancer Discovery, 2021, 11, 2780-2795.	9.4	125
4	The landscape of chromothripsis across adult cancer types. Nature Communications, 2020, 11, 2320.	12.8	75
5	Germline SDHBâ€inactivating mutation in gastric spindle cell sarcoma. Genes Chromosomes and Cancer, 2020, 59, 601-608.	2.8	4
6	Comprehensive genomic characterization of gene therapy-induced T-cell acute lymphoblastic leukemia. Leukemia, 2020, 34, 2785-2789.	7.2	4
7	Targetable ERBB2 mutations identified in neurofibroma/schwannoma hybrid nerve sheath tumors. Journal of Clinical Investigation, 2020, 130, 2488-2495.	8.2	23
8	Metabolome-guided genomics to identify pathogenic variants in isocitrate dehydrogenase, fumarate hydratase, and succinate dehydrogenase genes in pheochromocytoma and paraganglioma. Genetics in Medicine, 2019, 21, 705-717.	2.4	60
9	Novel truncating PPM1D mutation in a patient with intellectual disability. European Journal of Medical Genetics, 2019, 62, 70-72.	1.3	10
10	Synergistic Highly Potent Targeted Drug Combinations in Different Pheochromocytoma Models Including Human Tumor Cultures. Endocrinology, 2019, 160, 2600-2617.	2.8	24
11	Optimizing Genetic Workup in Pheochromocytoma and Paraganglioma by Integrating Diagnostic and Research Approaches. Cancers, 2019, 11, 809.	3.7	23
12	Targeted capture-based NGS is superior to multiplex PCR-based NGS for hereditary BRCA1 and BRCA2 gene analysis in FFPE tumor samples. BMC Cancer, 2019, 19, 396.	2.6	30
13	Response to olaparib in a PALB2 germline mutated prostate cancer and genetic events associated with resistance. Journal of Physical Education and Sports Management, 2019, 5, a003657.	1.2	36
14	Defective homologous recombination DNA repair as therapeutic target in advanced chordoma. Nature Communications, 2019, 10, 1635.	12.8	64
15	A frameshift mutation in BRCA1 leads to hereditary breast and ovarian cancer in one part of a family and to familial pancreatic cancer in another. Breast Cancer Research and Treatment, 2018, 167, 305-307.	2.5	1
16	Next-generation panel sequencing identifies NF1 germline mutations in three patients with pheochromocytoma but no clinical diagnosis of neurofibromatosis type 1. European Journal of Endocrinology, 2018, 178, K1-K9.	3.7	19
17	Diagnostic value of partial exome sequencing in developmental disorders. PLoS ONE, 2018, 13, e0201041.	2.5	36
18	Skewed Xâ€inactivation in a family with DLG3â€associated Xâ€linked intellectual disability. American Journal of Medical Genetics, Part A, 2017, 173, 2545-2550.	1.2	12